Otiflox is used to treat bacterial infections in many different parts of the body. Otiflox oral liquid and tablets are also used to treat anthrax infection after inhalational exposure. Otiflox may mask or delay the symptoms of syphilis. It is not effective against syphilis infections.
Otiflox extended-release tablets are only used to treat urinary tract infections, including acute uncomplicated pyelonephritis.
Proquin® XR tablets are only used to treat uncomplicated or simple urinary tract infections (acute cystitis).
Otiflox belongs to the class of drugs known as quinolone antibiotics. It works by killing bacteria or preventing their growth. However, Otiflox will not work for colds, flu, or other virus infections.
Otiflox is available only with your doctor's prescription.
Otiflox indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Otiflox Tablets, USP are indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below.
Urinary Tract Infections
Otiflox Tablets, USP are indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis.
Acute Uncomplicated Cystitis
Otiflox Tablets, USP are indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus.
Chronic Bacterial Prostatitis
Otiflox Tablets, USP are indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis.
Lower Respiratory Tract Infections
Otiflox Tablets, USP are indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, Otiflox Tablets, USP are indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis.
Acute Sinusitis
Otiflox Tablets, USP are indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.
Skin and Skin Structure Infections
Otiflox Tablets, USP are indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes.
Bone and Joint Infections
Otiflox Tablets, USP are indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa.
Complicated Intra-Abdominal Infections
Otiflox Tablets, USP are indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis.
Infectious Diarrhea
Otiflox Tablets, USP are indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii†, Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated.
†Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients.
Typhoid Fever (Enteric Fever)
Otiflox Tablets, USP are indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of Otiflox in the eradication of the chronic typhoid carrier state has not been demonstrated.
Uncomplicated Cervical and Urethral Gonorrhea
Otiflox Tablets, USP are indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae.
Complicated Urinary Tract Infections and Pyelonephritis
Otiflox Tablets, USP are indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli.
Inhalational Anthrax (post-exposure)
Otiflox Tablets, USP are indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
Otiflox serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for Otiflox for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001.
Plague
Otiflox Tablets, USP are indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of Otiflox could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only.
Limitation of Use
Use in Pediatric Patients
Although effective in clinical trials, Otiflox is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Otiflox Tablets, USP, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals.
Lower Respiratory Tract Infections
Otiflox Tablets, USP are not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae.
Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Otiflox Tablets, USP and other antibacterial drugs, Otiflox Tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to Otiflox. Therapy with Otiflox Tablets, USP may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Otiflox. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.
How should I use Otiflox?
Use Otiflox suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Otiflox suspension comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Otiflox suspension refilled.
An extra patient leaflet may be available with Otiflox suspension. Talk to your pharmacist if you have questions about this information.
Take Otiflox suspension by mouth with or without food. The preferred dosing time is 2 hours after a meal.
Shake well before each use.
Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
Take Otiflox suspension with a full glass of water (8 oz [240 mL]).
Drinking extra fluids while you are taking Otiflox suspension is recommended. Check with your doctor for instructions.
If you also take any products containing magnesium, aluminum, calcium, iron, or zinc (eg, antacids, quinapril, vitamins/minerals); didanosine; sucralfate; or bismuth subsalicylate, do not take them within 6 hours before or 2 hours after taking Otiflox suspension. Check with your doctor if you have questions.
If you also take sevelamer, do not take it within 4 hours before or after taking Otiflox suspension. Check with your doctor if you have questions.
Otiflox suspension works best if it is taken at the same time each day.
To clear up your infection completely, take Otiflox suspension for the full course of treatment. Keep taking it even if you feel better in a few days.
Avoid taking Otiflox suspension with milk or milk products (eg, calcium-enriched juice, yogurt) by themselves. However, taking Otiflox suspension as part of a full meal that contains milk or milk products is permitted.
Do not miss any doses. If you miss a dose of Otiflox suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Otiflox suspension.
Uses of Otiflox in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
Use: Labeled Indications
Children and Adolescents: Treatment of complicated urinary tract infections and pyelonephritis due to E. coli. Note: Although effective, Otiflox is not the drug of first choice in children.
Infants, Children, Adolescents, and Adults: Prophylaxis to reduce incidence or progression of disease following inhalation exposure to Bacillus anthracis; prophylaxis and treatment of plague (Yersinia pestis).
Adults: Treatment of the following infections when caused by susceptible bacteria: Urinary tract infections; acute uncomplicated cystitis in females, chronic bacterial prostatitis, bone and joint infections, complicated intra-abdominal infections (in combination with metronidazole), infectious diarrhea, typhoid fever (Salmonella typhi), hospital-acquired (nosocomial) pneumonia.
Limitations of use: Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects), reserve Otiflox for use in patients who have no alternative treatment options for acute uncomplicated cystitis.
Off Label Uses
Anthrax
Based on the Centers for Disease Control and Prevention (CDC) expert panel meetings on prevention and treatment of anthrax, Otiflox is an effective and recommended agent for treatment of cutaneous or systemic anthrax.
Bite wound infection (animal and human bites)
Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTIs), Otiflox, in combination with an appropriate agent for anaerobes, is an effective and recommended alternative option for prophylaxis and treatment of human or animal bite wounds, particularly in patients who are hypersensitive to beta-lactams.
Data from a limited number of patients suggest that Otiflox may be beneficial for the treatment of cat scratch disease ).
Tularemia
Data from retrospective studies and case reports/series demonstrate varied results with the use of Otiflox in the management of tularemia. Guidelines created by the Infectious Diseases Society of America, Working Group on Civilian Biodefense, and the European Commission's Task Force on Biological and Chemical Agent Threats (BICHAT) recommend Otiflox as an alternative in the management of mild tularemia infection. In scenarios of mass casualty management and postexposure prophylaxis, the Working Group on Civilian Biodefense considers oral Otiflox and doxycycline as drugs of choice.
Otiflox description
sponsored
Otiflox: Each 250- and 500-mg tablet contains Ciprofloxacin HCl 250 mg and 500 mg, respectively.
Each 50-, 100- and 200-mL vial of infusion solution contains Ciprofloxacin lactate 100 mg, 200 mg and 400 mg, respectively.
Otiflox tablet also contains microcrystalline cellulose, maize starch, crospovidone, anhydrous colloidal silica, magnesium stearate, hypromellose, macrogol 4000 and titanium dioxide (E171) while the infusion solution also contains lactic acid, sodium chloride, concentrated hydrochloric acid and water for injections.
Otiflox XR: Each 500 mg tablet contains Ciprofloxacin HCl monohydrate 334.8 mg and Otiflox hydrous 253 mg, corresponding to Otiflox 500 mg. Each 1 g tablet contains Ciprofloxacin HCl monohydrate 669.4 mg and Otiflox hydrate 506 mg, corresponding to Otiflox 1000 mg.
Otiflox XR also contains the following excipients: Crospovidone, magnesium stearate, anhydrous colloidal silica, succinic acid, hypromellose, macrogol 3350, titanium dioxide and purified water in bulk.
Otiflox dosage
sponsored
Otiflox Dosage
Generic name: Otiflox HYDROCHLORIDE 500mg
Dosage form: tablet, film coated, extended release
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Otiflox and other oral formulations of Otiflox are not interchangeable. Otiflox should be administered orally once daily for 3 days with a main meal of the day, preferably the evening meal. Otiflox should be administered at least 4 hours before or 2 hours after antacids containing magnesium or aluminum, sucralfate, VIDEX® (didanosine) chewable/buffered tablets or pediatric powder, metal cations such as iron, and multivitamin preparations containing zinc.
Otiflox tablets should be taken whole and never split, crushed, or chewed.
Impaired Renal Function:
Otiflox is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternate pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. No dosage adjustment is required for patient with uUTI and mild to moderate renal impairment. The efficacy of Otiflox has not been studied in patients with severe renal impairment.
Impaired Liver Function:
No dosage adjustment is required with Otiflox in patients with stable chronic cirrhosis. However, the pharmacokinetics of Otiflox in patients with acute hepatic insufficiency have not been fully elucidated.
As with some other quinolones, concurrent administration of Otiflox with theophylline may lead to elevated serum concentrations of theophylline, which may result in an increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, serum concentrations of theophylline should be monitored and dosage adjustments made as appropriate.
Antacids and Other Products Containing Multivalent Cations
Concurrent administration of quinolones, including Otiflox, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX® chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of Otiflox. Otiflox (Otiflox hcl) should be given either 2 hours after or at least 4 hours before these products. This time window is different than for other oral formulations of Otiflox, which are usually administered 2 hours before or 6 hours after antacids.
Calcium-containing Beverages
Concomitant administration of Otiflox with milk products or calcium-fortified juices alone should be avoided since decreased absorption of Otiflox is possible.
Warfarin
Quinolones, including Otiflox, have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be monitored if Otiflox (Otiflox hcl) is administered concomitantly with warfarin or other oral anticoagulants. Patients should also be monitored for evidence of bleeding.
Cyclosporine
Some quinolones, including Otiflox, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly. Cyclosporine whole blood trough concentrations should be monitored when given concomitantly with Otiflox (Otiflox hcl).
Methotrexate
Renal tubular transport of methotrexate may be inhibited by concomitant administration of Otiflox, potentially leading to increased plasma concentrations of methotrexate. This might increase the risk of methotrexate toxic reactions. Therefore, patients under methotrexate therapy should be carefully monitored when concomitant Otiflox therapy is indicated.
Phenytoin
Altered serum concentrations of phenytoin (increased and decreased) have been reported in patients receiving concomitant Otiflox. Phenytoin serum concentrations should be monitored when given concomitantly with Otiflox (Otiflox hcl).
Glyburide
The concomitant administration of Otiflox with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
Non-steroidal Anti-inflammatory Drugs (NSAIDs), but not Aspirin
NSAIDs in combination with very high doses of quinolones have been shown to provoke convulsions in nonclinical studies [see Nonclinical Toxicology.
Caffeine
Some quinolones, including Otiflox, have been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and prolongation of the serum half-life of caffeine.
Probenecid
Probenecid interferes with renal tubular secretion of Otiflox and produces increased concentrations of Otiflox in serum.
The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:
Tendon Effects
Hypersensitivity Reactions
Other Serious and Sometimes Fatal Reactions
Central Nervous System Effects
Clostridium difficile-Associated Diarrhea
Peripheral Neuropathy
Photosensitivity/Phototoxicity
Development of Drug Resistant Bacteria
Crystalluria and cylindruria have been reported with quinolones, including Otiflox. Therefore, adequate hydration of patients receiving Otiflox (Otiflox hcl) should be maintained to prevent the formation of highly concentrated urine.
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Otiflox (Otiflox hcl) in 524 patients in one clinical trial. The population studied had a mean age of 39 years (approximately 93.4% of the population were < 65 years of age), 100% were female, 77% were Caucasian and 7.4% were Black. Patients received Otiflox (Otiflox hcl) 500 mg once daily for 3 days. Patients were followed for approximately 5 weeks after the end of study drug dosing.
Discontinuation of Otiflox (Otiflox hcl) occurred in 1.4% of patients. Each of the discontinuations were for a different adverse reactions. Refer to Table 1.
The most common adverse reactions ( ≥ 2%) were fungal infection, nasopharyngitis, headache, and micturition urgency.
Table 1: Adverse reactions (regardless of relationship to study drug) occurring in ≥ 1% of Otiflox (Otiflox hcl) -treated patients (500 mg once daily for 3 days) during the entire study period compared to Otiflox-immediate release tablets (250 mg twice daily for 3 days)
Adverse Reaction
Otiflox
Otiflox-immediate release tablets
Nausea
1.4
2.4
Abdominal pain
1.7
1.2
Suprapubic pain
1.4
0.6
Urinary tract infection
10.8
9.8
Fungal infection
2.7
1.8
Upper respiratory tract infection
1.4
2.9
Back pain
1.7
1.6
Headache
2.3
3.9
Micturition urgency
1.9
1.0
Urinary frequency
1.4
1.0
Nasopharyngitis
2.7
1.4
Pharyngitis
1.2
1.0
The incidence of adverse events (regardless of relationship to study drug) reported for at least 1% of patients treated with Otiflox (Otiflox hcl) during study drug treatment and up to 3 days after study drug was headache (1.5%).
Less common reactions, occurring at any time during the study in less than 1% of Otiflox (Otiflox hcl) -treated patients were:
Adverse Reactions Reported with Other Systemic Formulations of Otiflox
In addition, to the adverse reactions reported with Otiflox (Otiflox hcl), the following adverse reactions have been reported during clinical trials and from worldwide post-marketing experience with other systemic formulations of Otiflox (includes all dosages and indications).
Because these reactions have been reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or a causal relationship to drug exposure. Abnormal gait, achiness, acidosis, agitation, agranulocytosis, allergic reactions (ranging from urticaria to anaphylactic reactions), amylase increase, anemia, angina pectoris, angioedema, anosmia, anxiety, arrhythmia, arthralgia, ataxia, atrial flutter, bleeding diathesis, blurred vision, bronchospasm, C. difficile associated diarrhea, candidiasis (cutaneous, oral), candiduria, cardiac murmur, cardiopulmonary arrest, cardiovascular collapse, cerebral thrombosis, chills, cholestatic jaundice, chromatopsia, confusion, convulsion, delirium, depression, diplopia, drowsiness, dysphagia, dyspnea, edema (conjunctivae, face, hands, laryngeal, lips, lower extremities, neck, pulmonary), epistaxis, erythema multiforme, erythema nodosum, exfoliative dermatitis, fever, fixed eruptions, flushing, gastrointestinal bleeding, gout (flare up), grand mal convulsion, gynecomastia, hallucinations, hearing loss, hematuria, hemolytic anemia, hemoptysis, hemorrhagic cystitis, hepatic failure (including fatal cases), hepatic necrosis, hepatitis, hiccup, hyperesthesia, hyperpigmentation, hypertension, hypertonia, hypoesthesia, hypotension, ileus, insomnia, interstitial nephritis, intestinal perforation, jaundice, joint stiffness, lethargy, lightheadedness, lipase increase, lymphadenopathy, malaise, manic reaction, marrow depression, migraine, moniliasis (oral, gastrointestinal, vaginal), mouth dryness, myalgia, myasthenia, myasthenia gravis (possible exacerbation), myocardial infarction, myoclonus, nephritis, nightmares, nystagmus, oral ulceration, pain (arm, back, breast, chest, epigastric, eye, extremities, foot, jaw, neck, oral mucosa), palpitation, pancreatitis, pancytopenia, paranoia, paresthesia, peripheral neuropathy, perspiration (increased), petechia, phlebitis, phobia, photosensitivity/phototoxicity reaction pleural effusion, polyuria, postural hypotension, prothrombin time prolongation, pseudomembranous colitis (the onset of symptoms may occur during or after antimicrobial treatment), pulmonary embolism, purpura, renal calculi, renal failure, respiratory arrest, respiratory distress, restlessness, serum sickness-like reaction, Stevens-Johnson syndrome, sweating, syncope, tachycardia, taste loss, tendonitis, tendon rupture, tinnitus, torsade de pointes, toxic epidermal necrolysis, toxic psychosis, tremor, twitching, unresponsiveness, urethral bleeding, urinary retention, urination (frequent), vaginal pruritus, vasculitis, ventricular ectopy, vesicles, visual acuity (decreased), visual disturbances (flashing lights, change in color perception, overbrightness of lights), weakness.
The following adverse laboratory changes, in alphabetical order, regardless of incidence or relationship to drug, have been reported in patients given Otiflox (includes all formulations, all dosages, all drug-therapy durations, and all indications):
Decreases in blood glucose, BUN, hematocrit, hemoglobin, leukocyte counts, platelet counts, prothrombin time, serum albumin, serum potassium, total serum protein, uric acid.
You should not use this medication if you are taking tizanidine (Zanaflex), if you have a history of myasthenia gravis, or if you are allergic to Otiflox or similar antibiotics such as gemifloxacin (Factive), levofloxacin (Levaquin), moxifloxacin (Avelox), norfloxacin (Noroxin), and others.
Before taking Otiflox, tell your doctor if you have a heart rhythm disorder, kidney or liver disease, joint problems, diabetes, muscle weakness or trouble breathing, a condition called pseudotumor cerebri, a history of seizures, a history of head injury or brain tumor, low levels of potassium in your blood, a personal or family history of Long QT syndrome, or if you have ever had an allergic reaction to an antibiotic.
Do not take Otiflox with dairy products such as milk or yogurt, or with calcium-fortified juice.
Avoid taking antacids, vitamin or mineral supplements, sucralfate (Carafate), or didanosine (Videx) powder or chewable tablets within 6 hours before or 2 hours after you take Otiflox.
Otiflox may cause swelling or tearing of a tendon (the fiber that connects bones to muscles in the body), especially in the Achilles' tendon of the heel. Stop taking Otiflox and call your doctor at once if you have sudden pain, swelling, tenderness, stiffness, or movement problems in any of your joints. Rest the joint until you receive medical care or instructions.
DailyMed. "LIDOCAINE; TETRACAINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
DailyMed. "OFLOXACIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
DailyMed. "BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Otiflox are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Otiflox. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
1 consumer reported price estimates
Was the price you paid to purchase the drug reasonable? Did you feel it was expensive? The below mentioned numbers have been reported by ndrugs.com website users about whether the Otiflox drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
Users
%
Not expensive
1
100.0%
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!